Login / Signup

Cannabis allergy: what the clinician needs to know in 2019.

Ine Ilona DecuyperHans-Peter RihsAthina Ludovica Van GasseJessy ElstLeander De PuysseleyrMargaretha Antje FaberChristel H MertensMargo Maria HagendorensVito SabatoChris H BridtsLuc De ClerckDidier Gaston Ebo
Published in: Expert review of clinical immunology (2019)
Although the use of cannabis dates back millennia, the first description of cannabis allergy is relatively recent (1971). Recent large-scale data show that cannabis allergy can manifest severe and generalized symptoms with extensive cross-reactions. Thus, it is essential to become familiarized with its clinical presentation, diagnostic aids, and adequate therapeutic guidance. Areas covered: Here we provide a hands-on overview on cannabis allergy focusing on symptomatology and the reliability of diagnostic options. Recent advances in proteomics are discussed in detail, elucidating the link with nsLTP-related allergies. The proteomics advancements have paved the way for more reliable diagnostics, especially component-based tools. Finally, the current experience in treatment options is highlighted. Expert opinion: Cannabis allergy is an allergy entity which can significantly impact the quality of life. For optimal diagnosis, we advise to start with a validated and standardized crude-extract based test such as sIgE hemp complemented by component-based diagnostics such as sIgE Can s 3 quantifications where available. Future research should lift the veil on the true prevalence of cannabis allergy and the importance of other cannabis allergens to further guide our practice.
Keyphrases
  • atopic dermatitis
  • healthcare
  • mass spectrometry
  • primary care
  • risk factors
  • early onset
  • machine learning
  • electronic health record
  • artificial intelligence
  • sleep quality